152 related articles for article (PubMed ID: 37951315)
1. Digestion is a critical element for absorption of cinnarizine from supersaturated lipid-based type I formulations.
Paulus F; Bauer-Brandl A; Stappaerts J; Holm R
Eur J Pharm Sci; 2024 Jan; 192():106634. PubMed ID: 37951315
[TBL] [Abstract][Full Text] [Related]
2. Absorption of cinnarizine from type II lipid-based formulations: Impact of lipid chain length, supersaturation, digestion, and precipitation inhibition.
Paulus F; Holm R; Stappaerts J; Bauer-Brandl A
Eur J Pharm Sci; 2024 Jun; 197():106765. PubMed ID: 38608735
[TBL] [Abstract][Full Text] [Related]
3. Exploring precipitation inhibitors to improve in vivo absorption of cinnarizine from supersaturated lipid-based drug delivery systems.
Ilie AR; Griffin BT; Vertzoni M; Kuentz M; Kolakovic R; Prudic-Paus A; Malash A; Bohets H; Herman J; Holm R
Eur J Pharm Sci; 2021 Apr; 159():105691. PubMed ID: 33359616
[TBL] [Abstract][Full Text] [Related]
4. 'Stealth' lipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug.
Feeney OM; Williams HD; Pouton CW; Porter CJ
J Control Release; 2014 Oct; 192():219-27. PubMed ID: 25058571
[TBL] [Abstract][Full Text] [Related]
5. Gastric pre-processing is an important determinant of the ability of medium-chain lipid solution formulations to enhance oral bioavailability in rats.
Lee KW; Porter CJ; Boyd BJ
J Pharm Sci; 2013 Nov; 102(11):3957-65. PubMed ID: 23983139
[TBL] [Abstract][Full Text] [Related]
6. Effects of Lipid Digestion and Drug Permeation/Re-Dissolution on Absorption of Orally Administered Ritonavir as Different Lipid-Based Formulations.
Tanaka Y; Doi H; Katano T; Kasaoka S
Eur J Pharm Sci; 2021 Feb; 157():105604. PubMed ID: 33098990
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Digestion-In Situ Absorption Setup Employing a Physiologically Relevant Value of the Membrane Surface Area/Volume Ratio for Evaluating Performance of Lipid-Based Formulations: A Comparative Study with an In Vitro Digestion-Permeation Model.
Tanaka Y; Arai H; Hidaka A; Noda S; Imai K; Tsujisawa F; Yagi H; Sakuma S
Mol Pharm; 2024 Jul; 21(7):3459-3470. PubMed ID: 38809159
[TBL] [Abstract][Full Text] [Related]
8. In vitro assessment of drug-free and fenofibrate-containing lipid formulations using dispersion and digestion testing gives detailed insights into the likely fate of formulations in the intestine.
Devraj R; Williams HD; Warren DB; Mohsin K; Porter CJ; Pouton CW
Eur J Pharm Sci; 2013 Jul; 49(4):748-60. PubMed ID: 23684915
[TBL] [Abstract][Full Text] [Related]
9. Transformation of poorly water-soluble drugs into lipophilic ionic liquids enhances oral drug exposure from lipid based formulations.
Sahbaz Y; Williams HD; Nguyen TH; Saunders J; Ford L; Charman SA; Scammells PJ; Porter CJ
Mol Pharm; 2015 Jun; 12(6):1980-91. PubMed ID: 25905624
[TBL] [Abstract][Full Text] [Related]
10. Enabling superior drug loading in lipid-based formulations with lipophilic salts for a brick dust molecule: Exploration of lipophilic counterions and in vitro-in vivo evaluation.
Sirvi A; Jadhav K; Sangamwar AT
Int J Pharm; 2024 May; 656():124108. PubMed ID: 38604540
[TBL] [Abstract][Full Text] [Related]
11. The effect of administered dose of lipid-based formulations on the in vitro and in vivo performance of cinnarizine as a model poorly water-soluble drug.
Lee KW; Porter CJ; Boyd BJ
J Pharm Sci; 2013 Feb; 102(2):565-78. PubMed ID: 23242691
[TBL] [Abstract][Full Text] [Related]
12. Lipolysis-Permeation Setup for Simultaneous Study of Digestion and Absorption in Vitro.
Keemink J; Mårtensson E; Bergström CAS
Mol Pharm; 2019 Mar; 16(3):921-930. PubMed ID: 30628771
[TBL] [Abstract][Full Text] [Related]
13. Toward the establishment of standardized in vitro tests for lipid-based formulations. 5. Lipolysis of representative formulations by gastric lipase.
Bakala-N'Goma JC; Williams HD; Sassene PJ; Kleberg K; Calderone M; Jannin V; Igonin A; Partheil A; Marchaud D; Jule E; Vertommen J; Maio M; Blundell R; Benameur H; Müllertz A; Pouton CW; Porter CJ; Carrière F
Pharm Res; 2015 Apr; 32(4):1279-87. PubMed ID: 25288015
[TBL] [Abstract][Full Text] [Related]
14. Fenofibrate oral absorption from SNEDDS and super-SNEDDS is not significantly affected by lipase inhibition in rats.
Michaelsen MH; Siqueira Jørgensen SD; Abdi IM; Wasan KM; Rades T; Müllertz A
Eur J Pharm Biopharm; 2019 Sep; 142():258-264. PubMed ID: 31276759
[TBL] [Abstract][Full Text] [Related]
15. Digestion of Lipid-Based Formulations Not Only Mediates Changes to Absorption of Poorly Soluble Drugs Due to Differences in Solubilization But Also Reflects Changes to Thermodynamic Activity and Permeability.
Tanaka Y; Nguyen TH; Suys EJA; Porter CJH
Mol Pharm; 2021 Apr; 18(4):1768-1778. PubMed ID: 33729806
[TBL] [Abstract][Full Text] [Related]
16. Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623.
McEvoy CL; Trevaskis NL; Feeney OM; Edwards GA; Perlman ME; Ambler CM; Porter CJH
Mol Pharm; 2017 Dec; 14(12):4525-4538. PubMed ID: 29076741
[TBL] [Abstract][Full Text] [Related]
17. Effect of lipids on absorption of carvedilol in dogs: Is coadministration of lipids as efficient as a lipid-based formulation?
Alskär LC; Parrow A; Keemink J; Johansson P; Abrahamsson B; Bergström CAS
J Control Release; 2019 Jun; 304():90-100. PubMed ID: 31047962
[TBL] [Abstract][Full Text] [Related]
18.
Huang Y; Yu Q; Chen Z; Wu W; Zhu Q; Lu Y
Acta Pharm Sin B; 2021 Aug; 11(8):2469-2487. PubMed ID: 34522595
[TBL] [Abstract][Full Text] [Related]
19. Lipid-Based Formulations Can Enable the Model Poorly Water-Soluble Weakly Basic Drug Cinnarizine To Precipitate in an Amorphous-Salt Form During In Vitro Digestion.
Khan J; Rades T; Boyd BJ
Mol Pharm; 2016 Nov; 13(11):3783-3793. PubMed ID: 27631273
[TBL] [Abstract][Full Text] [Related]
20. Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion.
Williams HD; Anby MU; Sassene P; Kleberg K; Bakala-N'Goma JC; Calderone M; Jannin V; Igonin A; Partheil A; Marchaud D; Jule E; Vertommen J; Maio M; Blundell R; Benameur H; Carrière F; Müllertz A; Pouton CW; Porter CJ
Mol Pharm; 2012 Nov; 9(11):3286-300. PubMed ID: 23030411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
